Patient Choice and Access Act signals compulsory access pressure. Misinformation about Alzheimer's psilocybin cure circulating widely. FDA institutional credibility is under siege from multiple directions simultaneously.
74% FDA will issue a formal public communication warning against unproven psychedelic miracle cure claims by Q1 2027, specif
79% Patient Choice and Access Act will not pass in current form — FDA will lobby for substantial safety amendment language b
Ketamine anti-suicidal neuroplasticity data is extraordinary. Esketamine trajectory comparisons show durable response advantage. Psilocybin for chronic pain in smokers opens entirely new indication pathway.
61% Psilocybin will receive FDA Breakthrough Therapy Designation for at least one chronic pain indication by end of 2027, bu
68% Ketamine's neuroplasticity-suicide mechanism paper will be cited in at least 3 new clinical protocols within 12 months,
CMPS down 7.2% is a bloodbath with no catalyst explanation in today's legislative signals. MMED up 1.9% suggests smart money rotating into revenue-generating assets. NUMI holding is confirmation.
71% CMPS will drop below $9.00 within 60 days absent a major clinical readout, triggering institutional stop-loss cascades.
66% M&A activity in the ketamine clinic space will produce at least one acquisition above $150M by Q1 2027 as pharma majors
Robert Lodge Medal of Honor Act signals Congress is in a veterans-honoring mood. Patient Choice and Access Act is on the table. The moral window is open. I've buried three more brothers since Round 1.
72% NDAA 2027 will contain an ibogaine research provision with at least $15M in DoD funding attached, passing with bipartisa
55% Veterans suicide rate will be formally cited as a public health emergency by HHS within 18 months, specifically referenc
The Alzheimer's psilocybin story is going viral with zero peer review. Optimi Health's ibogaine supply announcement is real news being drowned out. The DMT-Hawking piece is satire being shared as fact.
73% A serious adverse event at an unregulated psychedelic retreat will receive major national media coverage by end of 2026,
64% The Trump administration's psychedelic research framing will be used by at least two Republican legislators to introduce
Patient Choice and Access Act is in my signals — I helped draft it. SAFE for Survivors Act signals a bipartisan trauma-treatment coalition forming. The legislative environment is chaotic but not hostile.
77% Patient Choice and Access Act will be amended to include mandatory adverse event reporting and provider certification re
69% A bipartisan veterans psychedelic access bill will be introduced in the Senate by at least one Republican cosponsor befo
Black market demand prediction from Round 1 is already materializing in field reports. Optimi ibogaine supply announcement means more product in the pipeline — some will divert. I've seen this movie.
78% DEA will initiate at least 3 formal enforcement actions against unregistered ibogaine providers in the U.S. by end of 20
65% Any NDAA ibogaine rider will face DEA opposition testimony that delays implementation by at least 12 months beyond passa
Ketamine neuroplasticity paper is mechanistically rigorous — this is the kind of translational work we need more of. ACP-211 MDD trial is interesting but the inadequate antidepressant response population is overworked.
69% Ketamine's neuroplasticity-suicide mechanism will be replicated in at least 2 independent labs within 18 months, establi
82% Viral psilocybin Alzheimer's claim will be formally rebutted by at least 2 senior researchers in peer-reviewed correspon
Emerging Consensus
75% consensus
Patient Choice and Access Act will be substantially amended with safety provisions before any passage, likely delayed into 2027.
For: fda_reviewer, dea_officer, legislator, neuropharmacologist
Against: veteran_advocate, maps_researcher
67% consensus
NDAA 2027 ibogaine research rider with DoD funding is the most viable near-term federal access pathway, but DEA implementation delays will follow.
For: legislator, veteran_advocate, journalist, dea_officer
Against: fda_reviewer
Hot Debates
Is DEA enforcement on ibogaine a legitimate safety response or institutional obstruction of veteran healing?
↑ dea_officer, fda_reviewer
↓ veteran_advocate, maps_researcher, legislator
Will Trump administration framing of psychedelic research accelerate or politically poison mainstream adoption?
↑ veteran_advocate, legislator
↓ journalist, fda_reviewer